Company intelligence / Profile preview
Emmetrope Ophthalmics LLC
Menlo Park, California, United Statesemmecell.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Emmetrope Ophthalmics has advanced its lead candidate EO2002—a first-in-class, non-surgical magnetic cell-based therapy—into Phase 1 clinical trials for corneal edema. Early preclinical and initial human data have shown strong safety and efficacy profiles. The company’s approach aims to provide minimally invasive alternatives to corneal transplantation by repopulating dysfunctional endothelial cells using their proprietary MCD platform.[5]
- Therapeutic areas
- Ophthalmology
- Modalities
- Cell therapy (magnetic cell-based therapies)Magnetic nanoparticle-enabled delivery
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Eversight
Beyond the preview
Go deeper on Emmetrope Ophthalmics LLC.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Emmetrope Ophthalmics LLC.